MDT - Medtronic plc
| Previous Close | 92.77 |
| Open | 92.72 |
| Bid | 92.00 x 900 |
| Ask | 94.47 x 800 |
| Day's Range | 92.72 - 94.60 |
| 52 Week Range | 76.41 - 100.15 |
| Volume | 7,922,006 |
| Avg. Volume | 5,181,489 |
| Market Cap | 126.543B |
| Beta (3Y Monthly) | 0.63 |
| PE Ratio (TTM) | 40.41 |
| EPS (TTM) | 2.32 |
| Earnings Date | Nov 20, 2018 |
| Forward Dividend & Yield | 2.00 (2.12%) |
| Ex-Dividend Date | 2018-09-27 |
| 1y Target Est | 104.00 |
- CNBC•yesterday
Cramer's game plan: Focus on opportunity as market awaits Fed, China news
The "Mad Money" host will be watching for include key housing data, as well as news on interest rates and a potential trade deal. CNBC's Jim Cramer will be seeking out "man-made" buying opportunities for investors in the short week before Thanksgiving Day. "Immediately, there were questions about ... the validity or the sincerity of both of these statements," Cramer noted, referencing his own concern about the Fed's lack of rigor in its policymaking.
GuruFocus.com•yesterdayStanley Druckenmiller Sells Facebook, Buys PayPal in 3rd Quarter
Tech enthusiast also ditches Netflix, Alibaba
GlobeNewswire•2 days agoNew Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System
November 16, 2018 - Medtronic plc (MDT) today announced new data on the Heli-FX(TM) EndoAnchor(TM) system, which demonstrated durability, safety and efficacy in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those with hostile aortic neck anatomies. The new data were unveiled in presentations at the 45th Annual Symposium of Vascular and Endovascular Issues (VEITHsymposium) in New York. The findings are based on three-year data from the primary prophylactic and therapeutic revision arms of the Medtronic ANCHOR registry - a global, multi-center, multi-arm, post-market registry evaluating the real-world applicability of the Heli-FX EndoAnchor System.
- Zacks•2 days ago
Will Strong RTG Arm Shape Medtronic's (MDT) Q2 Earnings?
Medtronic (MDT) poised to gain on continued RTG business growth in Q2.
- Zacks•2 days ago
Here's What Will Shape Medtronic's (MDT) Fate in Q2 Earnings
Medtronic (MDT) is expected to maintain a decent market share in the core pacing banking, backed by the continued rollout of Micra Transcatheter Pacing System.
- Zacks•3 days ago
Is Medtronic (MDT) Stock Outpacing Its Medical Peers This Year?
Is (MDT) Outperforming Other Medical Stocks This Year?
- Zacks•5 days ago
Medtronic (MDT) Reports Next Week: Wall Street Expects Earnings Growth
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•5 days ago
Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System
Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Broadens Treatable Patient Population with Thoracic Aortic Disease DUBLIN - November 13, 2018 - Medtronic plc (NYSE:MDT) today announced ...
- Motley Fool•6 days ago
Mazor Robotics Marks Time as It Waits to Be Acquired
The company's financial statements took a big step back during the quarter, but all eyes are on the pending Medtronic buyout.
- GlobeNewswire•9 days ago
Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2019
November 9, 2018 - Medtronic plc (MDT) announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. The news release will include summary financial information for the company`s second quarter of fiscal year 2019, which ended on Friday, October 26, 2018. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial results for its second quarter of fiscal year 2019.
- GlobeNewswire•10 days ago
Medtronic Delivers Significant Progress on Global Corporate Citizenship Efforts
2018 Integrated Performance Report Shows Improvement on Environmental Stewardship and Diversity Aspirational Goals DUBLIN - November 8, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, ...
- GlobeNewswire•10 days ago
Medtronic Begins Renal Denervation Study for High Blood Pressure Patients Prescribed Anti-Hypertensive Medication
November 8, 2018 - Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension) who are already prescribed anti-hypertension medications. The SPYRAL HTN-ON MED Trial is the latest prospectively powered, randomized, sham-controlled study within the broader Medtronic SPYRAL HTN Global Clinical Program, and will evaluate a patient population comparable to what physicians typically encounter in daily practice - patients with uncontrolled blood pressure taking multiple anti-hypertensive medications.
- GlobeNewswire•12 days ago
Medtronic Presents IN.PACT SFA Trial Five-Year Data and Total IN.PACT All-Subjects Analysis in VIVA Late Breaking Clinical Trials
November 6, 2018 - Medtronic plc (MDT) data presented today reinforce the durability, safety, and effectiveness of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. The five-year and final results from the pivotal IN.PACT SFA Trial and one-year all-subjects results from the Total IN.PACT Pooled Analysis were presented in two late-breaking clinical trial presentations at the Vascular Interventional Advances (VIVA) 2018 conference in Las Vegas. "Since the entrance of DCBs into the market several years ago, we have seen a shift towards the use of this technology as a frontline therapy to treat patients with PAD," said Mark Pacyna, vice president and general manager of the Peripheral business in the Medtronic Cardiac & Vascular Group.
- CNBC•15 days ago
Diabetics are hacking old insulin pumps to make them smarter — here's what happened when I tried it
Type 1 diabetes is a disease that affects more than 1.2 million Americans. It's a disease that impairs the body's ability to produce the hormone insulin, which normally comes from the pancreas. Managing blood sugars can be very difficult, and patients use a pump to help mimic the activity of the pancreas.
- Zacks•16 days ago
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
Medtronic (MDT) closed at $91.55 in the latest trading session, marking a +1.93% move from the prior day.
- Investor's Business Daily•16 days ago
IBD Stock Of The Day Breaks Out On Strong Quarterly Report, Outlook
Repligen is the IBD Stock Of The Day after the bioprocessor broke out for the second time this year on its 15th straight quarter of double-digit sales growth. Shares rose.
- Zacks•17 days ago
United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips
United Therapeutics (UTHR) beats estimates for both earnings and sales in the third quarter but shares sink 10%.
- Zacks•18 days ago
IntriCon (IIN) to Report Q3 Earnings: What's in the Cards?
IntriCon's (IIN) robust medical and hearing health businesses are likely to drive its third-quarter 2018 results.
Markit•18 days agoSee what the IHS Markit Score report has to say about Medtronic PLC.
Medtronic PLC NYSE:MDT
- Market Realist•19 days ago
Sanofi: Analysts’ Recommendations on October 30
Wall Street analysts expect Sanofi’s (SNY) third-quarter revenues to increase 3.3% to 9.3 billion euros. Sanofi’s stock price has decreased nearly 11.0% over the last 12 months. The stock price has decreased ~1.7% in 2018 year-to-date.
- Simply Wall St.•19 days ago
What Kind Of Shareholders Own Medtronic plc (NYSE:MDT)?
A look at the shareholders of Medtronic plc (NYSE:MDT) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual to Read More...
Market Realist•20 days agoWhy Morningstar Is Overweight on Healthcare
Following the September index review, the U.S. Moat Index remained overweight health care stocks. Rather than being an indication of Morningstar’s view of the sector as a whole, this reflects wide moat opportunities within the health care sector. The health care sector as a whole, as represented by the Morningstar US Healthcare Index, has fluctuated above and below fair value over the last five years, ending the period above fair value.
- GlobeNewswire•20 days ago
Research Report Identifies Chubb, DXC Technology, Medtronic, Snap-On, Euronet Worldwide, and Itron with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- The Wall Street Journal•20 days ago
[$$] Earl Bakken, Pacemaker
America’s affluent generation of millennial socialists don’t realize it, but they are living off the prosperity created by earlier generations of capitalists. One of them was Earl E. Bakken, who died last week at age 94 having invented the first wearable, battery-powered pacemaker. Earl Bakken’s business life is an American classic.
